Nyxoah SA Files 6-K Report
Ticker: NYXH · Form: 6-K · Filed: Aug 18, 2025 · CIK: 1857190
| Field | Detail |
|---|---|
| Company | Nyxoah SA (NYXH) |
| Form Type | 6-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, medical-devices
Related Tickers: NYXH
TL;DR
Nyxoah SA filed a 6-K, check for updates on sleep apnea device progress.
AI Summary
Nyxoah SA filed a 6-K report on August 18, 2025, for the period ending June 30, 2025. The filing includes information related to their sleep apnea device, clinical trials, and share-based payment arrangements. Specific financial figures or significant events are not detailed in the provided header information.
Why It Matters
This filing provides an update on Nyxoah's operational and financial activities, which is crucial for investors to assess the company's progress in the sleep apnea device market.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific financial or operational risks.
Key Players & Entities
- Nyxoah SA (company) — Filer
- 0001410578-25-001843 (filing_id) — Accession Number
- 20250818 (date) — Filing Date
- 20250630 (date) — Period of Report
- 3841 (sic_code) — Standard Industrial Classification
- Rue Edouard Belin 12 (address) — Business Address
- Mont-Saint-Guibert (city) — Business Address City
- BE (country) — Country of Incorporation
FAQ
What is the filing date of this 6-K report?
The filing date is August 18, 2025.
What period does this 6-K report cover?
The report covers the period ending June 30, 2025.
What is Nyxoah SA's Standard Industrial Classification code?
Nyxoah SA's SIC code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Where is Nyxoah SA's business address located?
Nyxoah SA's business address is Rue Edouard Belin 12, Mont-Saint-Guibert, C9.
What specific business segments or products are mentioned in the filing header?
The filing header mentions 'SleepApneaDeviceMember', 'FirstArticlesMember', 'ClinicalTrialsMember', and 'ActivationChipImprovementsMember'.
Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 16.9 · Accepted 2025-08-18 16:45:35
Filing Documents
- nyxh-20250630x6k.htm (6-K) — 302KB
- nyxh-20250630xex99d1.htm (EX-99.1) — 203KB
- nyxh-20250630xex99d2.htm (EX-99.2) — 2216KB
- nyxh-20250630xex99d1001.jpg (GRAPHIC) — 4KB
- 0001410578-25-001843.txt ( ) — 12863KB
- nyxh-20250630.xsd (EX-101.SCH) — 139KB
- nyxh-20250630_cal.xml (EX-101.CAL) — 101KB
- nyxh-20250630_def.xml (EX-101.DEF) — 293KB
- nyxh-20250630_lab.xml (EX-101.LAB) — 745KB
- nyxh-20250630_pre.xml (EX-101.PRE) — 541KB
- nyxh-20250630x6k_htm.xml (XML) — 3194KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NYXOAH SA Date: August 18, 2025 By: /s/ John Landry Name: John Landry Title: Chief Financial Officer 4